Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBernard Moss, Linda Wyatt, Patricia Earl
Life of this patent
Estimating the term…
Abstract
The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.
Claims23
A recombinant modified vaccinia Ankara (MVA) virus comprising a heterologous DNA sequence inserted into an intergenic region (IGR) of the MVA genome, wherein the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the MVA genome, and wherein the ORFs correspond to genes that are essential for replication of vaccinia virus.
A recombinant vaccinia virus comprising a heterologous DNA sequence inserted into an intergenic region (IGR) of the vaccinia virus genome, wherein the IGR is located between complete or partial sequences of two adjacent open reading frames (ORFs) of the vaccinia virus genome, and wherein the ORFs_correspond to genes that are essential for replication of vaccinia virus.
Dependencies are inferred from the claim text.